^
Association details:
Biomarker:AR-V7 mutation
Cancer:Prostate Cancer
Drug:onvansertib (PCM-075) (PLK1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

A Phase 2 Study of the Polo-like kinase 1 (PLK1) inhibitor, Onvansertib, in Combination with Abiraterone in Patients with Abiraterone (Abi)-Resistant Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Published date:
10/07/2020
Excerpt:
Onvansertib showed efficacy in patients with AR alterations [N = 8; AR-V7 (6)...3/8 (37%) achieved DC, 4 had SD, of whom 3 had durable SD (range 7 9mos)….Abi/prednisone + onvansertib is well tolerated and AE’s are effectively managed.
Trial ID: